VEXAS Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
VEXAS Syndrome Market Outlook Thelansis’s “VEXAS Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential VEXAS Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). VEXAS Syndrome Overview VEXAS syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) is a life-threatening, adult-onset autoinflammatory and hematologic disorder caused by acquired somatic mutations in the UBA1 gene of hematopoietic stem cells, predominantly affecting males over age 50. The mutation impairs the E1 ubiquitin-activating enzyme, triggering severe, treatment-resistant systemic inflammation alongside progressive bone mar...